
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ACCOLATE | Strides Pharma Global | N-020547 RX | 1996-09-26 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| accolate | New Drug Application | 2025-03-21 |
| zafirlukast | New Drug Application | 2025-07-31 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| asthma | EFO_0000270 | D001249 | J45 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Drug common name | Zafirlukast |
| INN | zafirlukast |
| Description | Zafirlukast is a member of indoles, a carbamate ester and a N-sulfonylcarboxamide. It has a role as an anti-asthmatic agent and a leukotriene antagonist. |
| Classification | Small molecule |
| Drug class | antiasthmatics/antiallergics (not acting primarily as antihistamines): leukotriene receptor antagonists |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12 |
| PDB | — |
| CAS-ID | 107753-78-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL603 |
| ChEBI ID | 10100 |
| PubChem CID | 5717 |
| DrugBank | DB00549 |
| UNII ID | XZ629S5L50 (ChemIDplus, GSRS) |






